Atossa Genetics, a Seattle, WA-based biotech developing diagnostic tests and treatments for breast cancer, registered with the SEC on Tuesday for a $6 million US IPO. Atossa began offering two diagnostics tests in December 2011 and hopes to offer two more by 2013. The biotech also has a proprietary treatment for pre-cancerous breast changes and could begin preclinical studies this year.
Atossa plans to offer 1 million shares at $5 to $7. At the midpoint, it would command a market value of $106 million. The company intends to list on the NASDAQ under the symbol ATOS. Dawson James Securities is managing the offering.
